Payment overview · 2025
General Payments
$2,712.56
32 reported records · 8 companies
Healthcare provider profile · identity verified
Blake Allen Badgett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WEATHERFORD, OK · NPI 1376636084
Verified facts
What the public records show
CMS Open Payments records show Blake Allen Badgett, M.D. received $2,712.56 in general payments during 2025 across 32 reported records.
Phathom Pharmaceuticals, Inc. accounted for 83.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,262.69 | 83.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $231.97 | 8.6% | 15 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $68.75 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.33 | 1.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.59 | 1.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.10 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.07 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.06 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,995.00 | 2 |
| Food and Beverage | $527.59 | 27 |
| Travel and Lodging | $101.00 | 1 |
| Education | $88.97 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $2,262.69 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $144.77 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $90.56 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.21 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $68.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 26 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
276 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 98 |
| Potassium Chloride | Potassium Chloride | 351 | 56 |
| Lisinopril | Lisinopril | 323 | 78 |
| Omeprazole | Omeprazole | 319 | 67 |
| Famotidine | Famotidine | 304 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 288 | 42 |
| Eliquis | Apixaban | 276 | 29 |
| Furosemide | Furosemide | 260 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 62 |
| Gabapentin | Gabapentin | 236 | 44 |
| Losartan Potassium | Losartan Potassium | 228 | 55 |
| Celecoxib | Celecoxib | 186 | 62 |
| Meloxicam | Meloxicam | 173 | 38 |
| Ozempic | Semaglutide | 168 | 20 |
| Farxiga | Dapagliflozin Propanediol | 145 | 26 |
| Mirtazapine | Mirtazapine | 134 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 22 |
| Januvia | Sitagliptin Phosphate | 121 | 18 |
| Pregabalin | Pregabalin | 121 | 24 |
| Carvedilol | Carvedilol | 119 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 28 |
| Simvastatin | Simvastatin | 116 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 32 |
| Metformin Hcl Er | Metformin Hcl | 98 | 28 |
| Tramadol Hcl | Tramadol Hcl | 98 | 26 |
| Trazodone Hcl | Trazodone Hcl | 98 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 24 |
| Metformin Hcl | Metformin Hcl | 94 | 23 |
| Sertraline Hcl | Sertraline Hcl | 94 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 22 |
| Levetiracetam | Levetiracetam | 85 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 27 |
| Risperidone | Risperidone | 83 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 18 |
| Montelukast Sodium | Montelukast Sodium | 79 | 18 |
| Bupropion Xl | Bupropion Hcl | 78 | 15 |
| Allopurinol | Allopurinol | 77 | 23 |
| Donepezil Hcl | Donepezil Hcl | 77 | 16 |
| Jardiance | Empagliflozin | 77 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 30 |
| Glimepiride | Glimepiride | 67 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 63 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 33 |
| Spironolactone | Spironolactone | 61 | 17 |
| Alprazolam | Alprazolam | 60 | 12 |
| Cephalexin | Cephalexin | 58 | 42 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 12 |
| Mupirocin | Mupirocin | 49 | 36 |
| Methenamine Hippurate | Methenamine Hippurate | 48 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Prednisone | Prednisone | 47 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 15 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Finasteride | Finasteride | 40 | 15 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Nystatin | Nystatin | 32 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Kerendia | Finerenone | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Torsemide | Torsemide | 27 | suppressed |
| Valproic Acid | Valproic Acid | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 25 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 21 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,712.56 · 32 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, CAPVAXIVE, COMIRNATY, ENFLONSIA, FARXIGA, Kerendia, Korlym, PENBRAYA, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, TRUMENBA, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error